CDEK
← All organizations

Sucampo

For profitContributed to NME

Also known as: Sucampo AG | Sucampo Pharma Americas, LLC | Sucampo Pharmaceuticals, Inc. | SUCAMPO PHARMA LLC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

May 1, 2005

First marketed drug

Aug 3, 2000

First NDA

Jan 31, 2006

Last known activity

Feb 13, 2017

Acquired by Mallinckrodt (2013) on Dec 26, 2017

Timeline

1990s

  1. Jan 1, 1996

    Sucampo— Founded

2000s

  1. Aug 3, 2000

    unoprostone isopropyl— NDA Secondary Org

  2. Jan 31, 2006

    lubiprostone— NDA Organization

2010s

  1. Jan 1, 2015

    R-Tech Ueno— Acquired

  2. Apr 3, 2017

    Vtesse Inc.— Acquired

  3. Dec 26, 2017

    Mallinckrodt (2013)— Acquired By

Drugs by trial phase (6 distinct, 28 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 2 (1 own, 1 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Subsidiaries (2 direct, 2 total across the full acquisition tree)

Recent trials (31)

Details

Founded
Bethesda, MD, US Jan 1, 1996
First NDA
Jan 31, 2006
Last known activity
Feb 13, 2017